Online citations, reference lists, and bibliographies.
← Back to Search

Brain Metastases In HER2-positive Breast Cancer: Challenges And Opportunities.

D. Torrejon, S. Di Cosimo
Published 2012 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The development of metastases in the central nervous system (CNS) is one of the most devastating consequences of breast cancer progression (1). Although epidemiologic studies estimate that the incidence of brain metastases (BM) in women with metastatic breast cancer (MBC) is 10-16% (2,3), reports from autopsies suggest rates of up to 30% (2,4,5).
This paper references
10.1002/1097-0142(19800701)46:1<162::AID-CNCR2820460127>3.0.CO;2-B
Causes of death in breast cancer a clinicopathologic study
F. Hagemeister (1980)
10.1002/cncr.23858
A phase 2 trial of whole‐brain radiotherapy combined with intravenous chemotherapy in patients with brain metastases from breast cancer
P. Cassier (2008)
10.1002/cncr.11436
Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma
J. Bendell (2003)
Sensitization of breast cancer cells to radiation by trastuzumab.
Ke Liang (2003)
10.1016/S1470-2045(12)70432-1
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.
T. Bachelot (2013)
10.1158/1078-0432.CCR-10-2962
Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER
A. Brufsky (2011)
10.1007/s11060-008-9791-2
Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients
Cyrus Chargari (2008)
10.1124/dmd.108.024646
An Unexpected Synergist Role of P-Glycoprotein and Breast Cancer Resistance Protein on the Central Nervous System Penetration of the Tyrosine Kinase Inhibitor Lapatinib (N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016)
J. Polli (2009)
10.1093/annonc/mdp343
Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study
S. Siena (2010)
10.1158/1078-0432.CCR-06-2842
A Patient Perspective on Brain Metastases in Breast Cancer
M. Mayer (2007)
10.1016/j.ijrobp.2010.06.057
Preliminary results of whole brain radiotherapy with concurrent trastuzumab for treatment of brain metastases in breast cancer patients.
Cyrus Chargari (2011)
Breast Cancer: Metastatic Patterns and Their Prognosis
O. Salazar (1988)
10.1093/AJCP/73.2.232
Causes of death and metastatic patterns in patients with mammary cancer. Ten-year autopsy study.
S. Y. Cho (1980)
10.1093/ANNONC/MDL064
Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG).
B. Pestalozzi (2006)
10.1200/JCO.2006.07.0250
Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer.
Z. Gabos (2006)
10.1007/s11060-007-9409-0
Capecitabine Therapy of Central Nervous System Metastases from Breast Cancer
M. Ekenel (2007)
10.1002/(SICI)1097-0142(19990401)85:7<1599::AID-CNCR23>3.0.CO;2-#
Front‐line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma
V. Franciosi (1999)
10.1007/s11060-004-9176-0
Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study
C. Christodoulou (2004)
10.1016/S1470-2045(09)70263-3
Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial.
Eric L. Chang (2009)
10.1002/1097-0142(19831215)52:12<2349::AID-CNCR2820521231>3.0.CO;2-B
Central nervous system metastasis from breast carcinoma autopsy study
Y. Tsukada (1983)
10.1007/s11060-011-0629-y
Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases
N. Lin (2011)
10.1023/A:1005835430489
Phase II trial of cisplatinum and etoposide in brain metastases of solid tumors
N. Viñolas (2004)
10.1002/cncr.23859
Phase 2 trial of temozolomide using protracted low‐dose and whole‐brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases
R. Addeo (2008)
10.1002/IJC.2910490504
Association of C‐erbB‐2 protein over‐expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long‐term survival in breast cancer
O. Kallioniemi (1991)



Semantic Scholar Logo Some data provided by SemanticScholar